VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.
View in:
PubMed
subject areas
Adult
Aged
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antigens, CD
Antigens, CD20
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols
Apoptosis
CD52 Antigen
Cytomegalovirus Infections
Disease Progression
Feasibility Studies
Female
Glycoproteins
Humans
Immunization, Passive
Lymphoma
Male
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Remission Induction
Rituximab
Safety
Salvage Therapy
Survival Analysis
Treatment Outcome
authors with profiles
MICHAEL ANDREEFF
HAGOP M KANTARJIAN
JORGE E CORTES
ALESSANDRA FERRAJOLI
SRDAN VERSTOVSEK
GUILLERMO GARCIA-MANERO
WILLIAM G WIERDA